LU93321I2 - Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci Download PDF

Info

Publication number
LU93321I2
LU93321I2 LU93321C LU93321C LU93321I2 LU 93321 I2 LU93321 I2 LU 93321I2 LU 93321 C LU93321 C LU 93321C LU 93321 C LU93321 C LU 93321C LU 93321 I2 LU93321 I2 LU 93321I2
Authority
LU
Luxembourg
Prior art keywords
disclosed
compounds
conditions
btk
ibrutinib
Prior art date
Application number
LU93321C
Other languages
English (en)
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39225888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93321(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of LU93321I2 publication Critical patent/LU93321I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
LU93321C 2006-09-22 2016-11-23 Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci LU93321I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82672006P 2006-09-22 2006-09-22
US82859006P 2006-10-06 2006-10-06
PCT/US2006/049626 WO2008039218A2 (fr) 2006-09-22 2006-12-28 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
LU93321I2 true LU93321I2 (fr) 2017-01-30

Family

ID=39225888

Family Applications (3)

Application Number Title Priority Date Filing Date
LU92662C LU92692I2 (fr) 2006-09-22 2015-04-07 Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci
LU93321C LU93321I2 (fr) 2006-09-22 2016-11-23 Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
LU00011C LUC00011I2 (fr) 2006-09-22 2017-03-30

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92662C LU92692I2 (fr) 2006-09-22 2015-04-07 Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00011C LUC00011I2 (fr) 2006-09-22 2017-03-30

Country Status (28)

Country Link
US (48) US7514444B2 (fr)
EP (11) EP2529621B1 (fr)
JP (4) JP4934197B2 (fr)
KR (4) KR20100051863A (fr)
CN (4) CN101610676B (fr)
AT (1) ATE531263T1 (fr)
AU (2) AU2006348662B8 (fr)
BR (2) BRPI0622277A2 (fr)
CA (3) CA3180977A1 (fr)
CY (11) CY1112513T1 (fr)
DK (7) DK2081435T3 (fr)
EA (3) EA020001B1 (fr)
ES (8) ES2564647T3 (fr)
FR (1) FR15C0029I2 (fr)
HK (3) HK1129274A1 (fr)
HU (10) HUE029095T2 (fr)
IL (1) IL197550A0 (fr)
LT (7) LT2529621T (fr)
LU (3) LU92692I2 (fr)
MX (3) MX2009003122A (fr)
NL (1) NL300728I2 (fr)
NZ (3) NZ575650A (fr)
PL (8) PL2526771T3 (fr)
PT (7) PT2201840E (fr)
SG (2) SG166093A1 (fr)
SI (8) SI2526933T1 (fr)
WO (1) WO2008039218A2 (fr)
ZA (4) ZA200901784B (fr)

Families Citing this family (519)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA89493C2 (uk) * 2004-04-02 2010-02-10 Оси Фармасьютикалз, Инк. 6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ
WO2007002093A2 (fr) * 2005-06-21 2007-01-04 Infinity Discovery, Inc. Formulations d'ansamycine et leurs procedes d'utilisation
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
SI2526933T1 (sl) * 2006-09-22 2015-07-31 Pharmacyclics, Inc. Inhibitorji Bruton tirozin kinaze
EP2089391B1 (fr) * 2006-11-03 2013-01-16 Pharmacyclics, Inc. Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20080255080A1 (en) * 2007-04-12 2008-10-16 Wright James L Hydroquinone Ansamycin Formulations
JP5600063B2 (ja) * 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2250173A1 (fr) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Dérivés d'imidazopyrazinol pour le traitement des cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101955914B1 (ko) 2008-06-27 2019-03-11 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2726460C (fr) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Nouvelles phenyl-imidazopyridines et pyridazines
AU2013245503B2 (en) * 2008-07-16 2015-09-24 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
KR101341876B1 (ko) * 2008-09-05 2013-12-20 셀진 아빌로믹스 리서치, 인코포레이티드 비가역 인히비터 디자인을 위한 알고리즘
WO2010043633A1 (fr) * 2008-10-15 2010-04-22 Palau Pharma, S. A. Dérivés de 2h-pyrazolo[4,3-d]pyrimidin-5-amine utilisés comme antagonistes des récepteurs h4 de l'histamine pour le traitement de maladies allergiques, immunologiques et inflammatoires
EP2348845A4 (fr) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc Compositions d'ansamycine hydroquinone
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
CA2752826A1 (fr) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation de c-pyrazine-methylamines
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2011029046A1 (fr) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs de tyrosine kinase de bruton
SG179083A1 (en) * 2009-09-11 2012-04-27 Cylene Pharmaceuticals Inc Pharmaceutically useful heterocycle-substituted lactams
SG179172A1 (en) * 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
US7965498B2 (en) 2009-09-30 2011-06-21 Apple Inc. Cover glass to housing interface system
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2937345B1 (fr) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
CA2792273A1 (fr) * 2010-03-08 2011-09-15 Ratiopharm Gmbh Composition pharmaceutique contenant du dabigatran etexilate
US9371567B2 (en) * 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
SG185617A1 (en) 2010-05-31 2012-12-28 Ono Pharmaceutical Co Purinone derivative
NZ789041A (en) 2010-06-03 2023-09-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120053189A1 (en) * 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
US8962830B2 (en) 2010-07-09 2015-02-24 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
CA2807051A1 (fr) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Sel de besylate d'un inhibiteur de btk
CN103119045B (zh) * 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
WO2012061303A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
JP5543039B2 (ja) 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
AU2012255759B2 (en) * 2011-05-17 2017-08-10 Principia Biopharma, Inc. Kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
KR102027598B1 (ko) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
WO2012158810A1 (fr) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Inhibiteurs de tyrosine kinase
AU2012275275A1 (en) * 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
UA115312C2 (uk) 2011-07-19 2017-10-25 Мерк Шарп І Доум Б.В. 4-імідазопіридазин-1-ілбензаміди і 4-імідазотриазин-1-ілбензаміди як втк-інгібітори
EP2548877A1 (fr) * 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
JP6506555B2 (ja) * 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
GB2496135B (en) 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
WO2013067260A1 (fr) * 2011-11-03 2013-05-10 Genentech, Inc. Composés pipérazines bicycliques
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9212381B2 (en) * 2011-11-10 2015-12-15 President And Fellows Of Harvard College Methods and compositions for labeling polypeptides
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
LT2786996T (lt) 2011-11-29 2017-01-10 Ono Pharmaceutical Co., Ltd. Purinono darinio hidrochloridas
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3366685A1 (fr) 2012-01-09 2018-08-29 X-Chem, Inc. Dérivés de tryptoline ayant une activité inhibitrice de kinase et leurs utilisations
EP2809673B1 (fr) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Molécules spirocycliques en tant qu'inhibiteurs de tyrosine kinase de bruton
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
CA2861980C (fr) * 2012-02-23 2016-11-08 Taiho Pharmaceutical Co., Ltd. Compose a cycle fusionne de quinolyl-pyrrolo-pyrimidyl ou un sel associe
CN103312670A (zh) 2012-03-12 2013-09-18 西安西电捷通无线网络通信股份有限公司 一种认证方法及系统
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
CN104302178B (zh) 2012-03-15 2018-07-13 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
WO2013152135A1 (fr) 2012-04-04 2013-10-10 Dawei Zhang Quinoléines substituées en tant qu'inhibiteurs de tyrosine kinases de bruton
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
EP2836214B1 (fr) 2012-04-11 2018-06-27 Acerta Pharma B.V. Inhibiteurs de la tyrosine kinase de bruton pour la mobilisation hématopoïétique
CN103374001B (zh) * 2012-04-19 2015-10-28 山东轩竹医药科技有限公司 咪唑并三嗪类mTOR抑制剂
KR101972990B1 (ko) * 2012-05-31 2019-04-26 파마사이언스 인크. 단백질 키나제 저해제
SG11201408067YA (en) * 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
MX368112B (es) * 2012-06-18 2019-09-18 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
JP6261580B2 (ja) * 2012-07-30 2018-01-17 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化イブルチニブ
WO2014022569A1 (fr) * 2012-08-03 2014-02-06 Principia Biopharma Inc. Traitement de la sécheresse oculaire
NZ703607A (en) 2012-08-10 2018-02-23 Boehringer Ingelheim Int Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
WO2014036016A1 (fr) 2012-08-31 2014-03-06 Principia Biopharma Inc. Dérivés de benzimidazole en tant qu'inhibiteurs d'itk
WO2014039899A1 (fr) * 2012-09-10 2014-03-13 Principia Biopharma Inc. Composés pyrazolopyrimidine utilisés comme inhibiteurs de kinase
CH706997A1 (en) 2012-09-20 2014-03-31 Ferag Ag Access control on operating modules of a control unit.
WO2014063068A1 (fr) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
US9717731B2 (en) * 2012-11-02 2017-08-01 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
CA2890934A1 (fr) 2012-11-15 2014-05-22 Pharmacyclics, Inc. Composes pyrrolopyrimidines en tant qu'inhibiteurs de kinase
BR112015011031A2 (pt) 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de grp40 de di-hidropirazol
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2935226A4 (fr) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc Composés hétéroarylés et leurs utilisations
KR20150111918A (ko) * 2012-12-21 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 경점막 전달
WO2014113932A1 (fr) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Inhibiteurs de btk
WO2014113942A1 (fr) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Inhibiteurs de btk
TW201441234A (zh) * 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
US20140357636A1 (en) * 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
WO2014129596A1 (fr) 2013-02-22 2014-08-28 大鵬薬品工業株式会社 Procédé de production de composé tricyclique, et composé tricyclique apte à être produit par ledit procédé de production
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US9610282B2 (en) * 2013-03-12 2017-04-04 Nbip, Llc Compositions and methods for preventing infection of a wound and for advancing the healing process
CN103142601A (zh) * 2013-03-13 2013-06-12 杭州雷索药业有限公司 Pci-32765在制备抗血管生成类药物中的应用
EP2968341A4 (fr) * 2013-03-14 2016-11-23 Pharmacyclics Llc Combinaisons d'inhibiteurs de tyrosine kinase de burton et d'inhibiteurs de cyp3a4
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
EP2970205B1 (fr) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
JP6495886B2 (ja) 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としての複素環式芳香族化合物
BR112015021856A2 (pt) 2013-03-15 2017-07-18 Janssen Pharmaceutica Nv processos e intermediários para a preparação de um medicamento
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EA201591656A1 (ru) * 2013-04-08 2016-05-31 Фармасайкликс Элэлси Комбинированная терапия с ибрутинибом
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
RS55770B1 (sr) 2013-04-25 2017-07-31 Beigene Ltd Fuzionisana heterociklična jedinjenja kao inhibitori protein kinaze
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
WO2014187319A1 (fr) 2013-05-21 2014-11-27 Jiangsu Medolution Ltd Pyrazolopyrimidines substituées utiles comme inhibiteurs de kinases
EP3016953A4 (fr) * 2013-07-02 2017-03-01 Pharmacyclics, LLC Composés purinones comme inhibiteurs de kinase
BR112015029972A2 (pt) 2013-07-03 2017-07-25 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
EP3027192A4 (fr) 2013-08-02 2017-03-22 Pharmacyclics, LLC Méthodes permettant de traiter des tumeurs solides
EP2832358A1 (fr) 2013-08-02 2015-02-04 Bionsil S.r.l. Kit pharmaceutique pour utilisation dans le traitement de cancer du côlon et colorectal
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
SG11201602421VA (en) 2013-09-30 2016-04-28 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
RU2677884C2 (ru) 2013-09-30 2019-01-22 Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
WO2015054197A1 (fr) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Inhibiteurs hdac, seuls ou en combinaison avec des inhibiteurs btk, pour traiter des lymphomes non-hodgkiniens
WO2015057992A1 (fr) 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
US20160272645A1 (en) * 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
EP3057955B1 (fr) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles dans le traitement de maladies proliferatives
EP3057970A1 (fr) 2013-10-18 2016-08-24 Medivation Technologies, Inc. Composés hétérocycliques et procédés d'utilisation
TWI620565B (zh) * 2013-10-25 2018-04-11 製藥公司 治療及預防移植物抗宿主病之方法
WO2015061752A1 (fr) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015071432A1 (fr) 2013-11-14 2015-05-21 Sandoz Ag Compositions pharmaceutiques à base d'ibrutinib
WO2015073833A1 (fr) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Méthodes permettant de retarder ou de prévenir l'apparition du diabète de type 1
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CA2833867A1 (fr) 2013-11-21 2015-05-21 Pharmascience Inc. Inhibiteurs de proteine kinase
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
TW202402295A (zh) * 2013-12-02 2024-01-16 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
EA201691169A1 (ru) 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
US9260415B2 (en) 2013-12-05 2016-02-16 Genentech, Inc. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2015089479A1 (fr) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
CA2932353A1 (fr) * 2013-12-13 2015-06-18 Steven P. Treon Procede pour traiter un lymphome lymphoplasmocytaire
US9834554B2 (en) 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3082809B1 (fr) * 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Inhibiteurs de btk
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
CN106008521A (zh) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015116485A1 (fr) 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Composés de pyrazole utilisés en tant qu'inhibiteurs de btk
CN105916859A (zh) * 2014-02-03 2016-08-31 卡迪拉保健有限公司 杂环化合物
EP3107544B1 (fr) 2014-02-21 2020-10-07 Principia Biopharma Inc. Sels et forme solide d'un inhibiteur de btk
WO2015131080A1 (fr) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
WO2015146159A1 (fr) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Agent prophylactique et/ou agent thérapeutique pour lymphome diffus à grandes cellules b
WO2015151006A1 (fr) * 2014-03-29 2015-10-08 Lupin Limited Composés de purine substitués en tant qu'inhibiteurs de btk
WO2015181633A2 (fr) 2014-04-11 2015-12-03 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton
WO2015185998A2 (fr) 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105085529A (zh) * 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
TW201613644A (en) 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
CN104945404B (zh) * 2014-06-25 2018-09-14 广东东阳光药业有限公司 一种n-丙烯羰基哌啶衍生物的制备方法
US9580416B2 (en) 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
CN105294571B (zh) 2014-07-03 2019-04-23 浙江九洲药业股份有限公司 一种依鲁替尼中间体及其制备方法和用途
CA2953798C (fr) * 2014-07-07 2019-06-11 Eternity Bioscience Inc. Composes aminopyridazinone a utiliser en tant qu'inhibiteurs de proteines kinases
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (fr) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2016020901A1 (fr) 2014-08-07 2016-02-11 Acerta Pharma B.V. Procédés de traitement de cancers, maladies immunitaires et auto-immunes, et maladies inflammatoires basés sur l'occupation de btk et le taux de resynthèse de btk
AU2015300798A1 (en) 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
CA2956550A1 (fr) 2014-08-08 2016-02-11 Pharmacyclics Llc Combinaisons d'inhibiteurs de tyrosine kinase de bruton et leurs utilisations
CN105461720B (zh) * 2014-08-08 2019-08-06 南京圣和药业股份有限公司 吗啉类酪氨酸激酶抑制剂
EP3179991B1 (fr) 2014-08-11 2021-10-06 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016024227A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
WO2016024232A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de la btk, d'un inhibiteur de la pi3k, d'un inhibiteur de la jak-2 et/ou d'un inhibiteur de la cdk 4/6
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
US10035802B2 (en) 2014-08-14 2018-07-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ibrutinib
CN106922146B (zh) 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
EP3209648B1 (fr) 2014-10-22 2020-03-11 Dana-Farber Cancer Institute, Inc. Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives
PE20190710A1 (es) 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
EP3212645B1 (fr) 2014-10-27 2018-11-28 F.Hoffmann-La Roche Ag Procédé pour la fabrication de composés de lactame tricyclique
WO2016066673A1 (fr) * 2014-10-30 2016-05-06 Sandoz Ag Synthèse de 1h-pyrazolo[3,4-d]pyrimidines substituées
US10196397B2 (en) 2014-11-19 2019-02-05 Sun Pharmaceutical Industries Limited Process for the preparation of ibrutinib
WO2016079216A1 (fr) 2014-11-20 2016-05-26 Sandoz Ag Formes physiques de l'ibrutinib, un inhibiteur de la kinase de bruton
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
WO2016088074A1 (fr) * 2014-12-03 2016-06-09 Dr. Reddy’S Laboratories Limited Procédé pour la préparation d'ibrutinib amorphe
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
CN104478884A (zh) * 2014-12-05 2015-04-01 广东东阳光药业有限公司 一种中间体的制备方法
WO2016087994A1 (fr) 2014-12-05 2016-06-09 Acerta Pharma B.V. Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
JP6679147B2 (ja) 2014-12-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016106652A1 (fr) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Inhibiteurs de btk à base de biaryléether d'imidazopyrazine
WO2016106624A1 (fr) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Inhibiteurs de la btk comprenant une imidazopyrazine d'alcool tertiaire
WO2016106628A1 (fr) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Inhibiteurs de btk
WO2016106629A1 (fr) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Inhibiteurs de btk
CN105820168B (zh) * 2015-01-09 2018-12-04 上海医药工业研究院 一种依鲁替尼中间体的制备方法
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
WO2016123504A1 (fr) * 2015-01-30 2016-08-04 Pharmacyclics Llc Combinaisons d'inhibiteur btk et multirésistance aux médicaments
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
CN107207519B (zh) * 2015-02-12 2019-11-08 正大天晴药业集团股份有限公司 伊布替尼的制备方法
WO2016132383A1 (fr) 2015-02-18 2016-08-25 Mylan Laboratories Limited Procédé pour la préparation d'ibrutinib
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
FI3265084T3 (fi) * 2015-03-03 2024-02-21 Pharmacyclics Llc Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
US10045990B2 (en) 2015-03-04 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University ERBB4 inhibitors and methods of use thereof
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
WO2016161248A1 (fr) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Ciblage des kinases pim associé à l'inhibition de btk
CN107873029B (zh) * 2015-04-02 2020-09-01 拉蒂奥法姆有限责任公司 依鲁替尼与羧酸的共晶体
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技（苏州）有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
ES2964472T3 (es) 2015-04-06 2024-04-08 Janssen Pharmaceutica Nv Composiciones que contienen ibrutinib
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
EP3281943B1 (fr) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Procédé de fabrication d'un dérivé de purinone
CN106146512B (zh) * 2015-04-09 2018-07-17 北京睿创康泰医药研究院有限公司 依鲁替尼的制备方法
US10485794B2 (en) 2015-04-13 2019-11-26 Daiichi Sankyo Company, Limited Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
CN106146482B (zh) * 2015-04-14 2020-06-23 宁波文达医药科技有限公司 布鲁顿酪氨酸激酶抑制剂
WO2016170545A1 (fr) * 2015-04-22 2016-10-27 Msn Laboratories Private Limited Procédé de préparation de 1-[(3r)-3-[4-amino-3-(4-phénoxyphényl)-1h- pyrazolo[3,4-d]pyriniidin-1-y1]-1-pipéridinyl]-2-propèn-1-one et de ses polymorphes
EP3195865A1 (fr) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs d'irak4 et inhibiteurs de btk
JP6847855B2 (ja) 2015-04-30 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ
US10617691B2 (en) 2015-05-26 2020-04-14 Morphosys Ag Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
EA039006B1 (ru) 2015-06-03 2021-11-19 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US9394312B1 (en) * 2015-06-14 2016-07-19 Mark Quang Nguyen Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
ES2909048T3 (es) * 2015-06-22 2022-05-05 Ono Pharmaceutical Co Compuesto inhibidor de Brk
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CZ2015442A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Ibrutinib hemisulfát
WO2016207172A1 (fr) * 2015-06-26 2016-12-29 Sandoz Gmbh Préparation d'ibrutinib amorphe pur
WO2017004134A1 (fr) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
US9650393B2 (en) 2015-07-02 2017-05-16 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
MY193514A (en) 2015-07-02 2022-10-17 Acerta Pharma Bv Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
ITUB20152576A1 (it) * 2015-07-29 2017-01-29 Laboratorio Chimico Int S P A Procedimento per la preparazione di ibrutinib e nuovo intermedio di sintesi.
KR20180040694A (ko) 2015-08-19 2018-04-20 썬 파마슈티칼 인더스트리스 리미티드 이브루티닙의 결정형 및 그 제조 방법
WO2017033113A1 (fr) 2015-08-21 2017-03-02 Acerta Pharma B.V. Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk
EP3344254A1 (fr) 2015-08-31 2018-07-11 Pharmacyclics LLC Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
EP3344624B8 (fr) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Inhibiteurs de tyk2 et leurs utilisations
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
EP3347018B1 (fr) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
WO2017044720A1 (fr) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Analogues de la rapamycine et leurs utilisations
CA2904270A1 (fr) * 2015-09-11 2017-03-11 Pharmascience Inc. Inhibiteurs de proteine kinase
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017046746A1 (fr) 2015-09-15 2017-03-23 Acerta Pharma B.V. Associations thérapeuthiques d'un inhibiteur de la btk et d'une molécule de liaison à gitr, d'un agoniste de 4-1bb, ou d'un agoniste d'ox40
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
JP2018530550A (ja) 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
SI3364958T1 (sl) 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
US9834561B2 (en) * 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
PT3377484T (pt) * 2015-11-17 2023-12-14 Merck Patent Gmbh Métodos para tratamento de esclerose múltipla utilizando compostos de pirimidina e piridina com atividade inibidora de btk
CN105294696A (zh) * 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
EP3383396B1 (fr) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib et venetoclax pour le traitement des lymphoms non hodgkiniens
EP4012415A3 (fr) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Procédés et compositions liés à la toxicité associée à une thérapie cellulaire
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
EP3389664A4 (fr) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Inhibiteurs de caféine de mthfd2 et leurs utilisations
DK3390390T3 (da) 2015-12-16 2021-12-06 Boehringer Ingelheim Int Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
EA035132B1 (ru) 2015-12-16 2020-04-30 Локсо Онколоджи, Инк. Соединения, которые можно применять в качестве ингибиторов киназы
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
WO2017123695A1 (fr) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Utilisation d'isoquinolones comme inhibiteurs de btk
MA43649A (fr) 2016-01-19 2018-11-28 Janssen Pharmaceutica Nv Formulations/compositions comprenant un inhibiteur de btk
MA43650A (fr) 2016-01-19 2018-11-28 Janssen Pharmaceutica Nv Formulations/compositions comprenant un inhibiteur de btk
US10662187B2 (en) 2016-01-21 2020-05-26 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
CN106995446B (zh) * 2016-01-22 2021-07-02 山东新时代药业有限公司 布鲁顿酪氨酸激酶抑制剂制备方法
CN105732638B (zh) * 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
US10626117B2 (en) 2016-02-01 2020-04-21 Natco Pharma Limited Process for the preparation of Ibrutinib
WO2017134685A2 (fr) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Nouveaux composés hydrazino utilisés comme inhibiteurs de btk
WO2017134588A1 (fr) 2016-02-04 2017-08-10 Shilpa Medicare Limited Procédé de préparation d'ibrutinib
WO2017133630A1 (fr) * 2016-02-05 2017-08-10 北京盛诺基医药科技有限公司 Inhibiteur de la tyrosine kinase de bruton
GB2558514A (en) * 2016-02-09 2018-07-18 Azad Pharmaceutical Ingredients Ag Process for the synthesis of stable amorphous ibrutinib
EP3416628A1 (fr) 2016-02-18 2018-12-26 Privo Technologies, Inc. Système et méthode d'administration d'agent thérapeutique à base de microparticules à deux étages
CN105646498A (zh) * 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN105646499A (zh) * 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
ES2912465T3 (es) 2016-03-11 2022-05-26 Angel Pharmaceutical Co Ltd Compuestos y métodos para modular la tirosina quinasa de Bruton
WO2017163257A1 (fr) * 2016-03-21 2017-09-28 Ind-Swift Laboratories Limited Procédé de préparation d'un dérivé lh-pyrazolo[3,4-d] pyrimidine pur
US20190105407A1 (en) 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
WO2017177230A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
KR20220054894A (ko) 2016-04-15 2022-05-03 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
PL3442535T3 (pl) 2016-04-15 2022-10-24 Cancer Research Technology Limited Związki heterocykliczne jako inhibitory kinazy ret
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
CN109152781A (zh) * 2016-04-29 2019-01-04 达纳-法伯癌症研究所有限公司 作为myd88突变疾病中的治疗靶标的hck
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
CN105859728B (zh) * 2016-05-26 2018-06-08 江苏中邦制药有限公司 一种依鲁替尼的制备方法
BR112018074238A2 (pt) 2016-05-27 2019-04-16 Tg Therapeutics, Inc. combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
WO2017216280A1 (fr) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indoles et utilisations associées
CN109311876B (zh) 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
RU2754856C2 (ru) * 2016-06-20 2021-09-08 Новартис Аг Кристаллические формы соединения триазолопиримидина
EP3471727B1 (fr) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
CN106117214A (zh) * 2016-06-29 2016-11-16 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
WO2018000250A1 (fr) * 2016-06-29 2018-01-04 上海创诺医药集团有限公司 Nouvelle forme cristalline ibrutinib et méthode de préparation de celle-ci
CN109311896B (zh) 2016-06-30 2021-08-24 株式会社大熊制药 吡唑并嘧啶衍生物作为激酶抑制剂
WO2018002958A1 (fr) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Nouveaux composés contenant de l'hydrazide utilisés comme inhibiteurs de btk
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
US10399988B2 (en) 2016-07-07 2019-09-03 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
CN107641123A (zh) * 2016-07-20 2018-01-30 南京亿华药业有限公司 一种依鲁替尼及其关键中间体的制备新方法
EP3487852A1 (fr) 2016-07-21 2019-05-29 Biogen MA Inc. Formes de succinate et compositions d'inhibiteurs de tyrosine kinase de bruton
CA3033827A1 (fr) 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyle)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa preparation et ses utilisations
WO2018033091A1 (fr) * 2016-08-17 2018-02-22 深圳市塔吉瑞生物医药有限公司 Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
AU2017326558B2 (en) 2016-09-19 2022-01-06 Mei Pharma, Inc. Combination therapy
CN109790121B (zh) * 2016-10-06 2024-01-05 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3527226A4 (fr) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited Procédé de polythérapie utilisant un inhibiteur de mdm2 et un inhibiteur d'adn méthyltransférase
EP3528816A4 (fr) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
CA3042049A1 (fr) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Polytherapie de type therapie cellulaire t et inhibiteur de btk
EP3538091A4 (fr) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. Inhibiteurs de la phényl amino pipéridine mtorc et leurs utilisations
CN108069974B (zh) * 2016-11-15 2019-12-10 杭州和正医药有限公司 一种选择性布鲁顿酪氨酸激酶抑制剂及其应用
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
WO2018106636A1 (fr) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Inhibiteurs de shmt et leurs utilisations
CN110291080B (zh) * 2016-12-21 2022-07-08 安塞塔制药公司 布鲁顿酪氨酸激酶的咪唑并吡嗪抑制剂
WO2018115203A1 (fr) 2016-12-23 2018-06-28 Bicyclerd Limited Dérivés peptidiques ayant de nouvelles structures de liaison
EP3565638B8 (fr) 2017-01-06 2024-04-10 BicycleRD Limited Conjugué bicyclique pour traiter le cancer
WO2018137681A1 (fr) 2017-01-25 2018-08-02 Beigene, Ltd. Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, préparation et utilisations associées
WO2018151849A1 (fr) 2017-02-17 2018-08-23 Privo Technologies, Inc. Dispositif et méthode d'administration d'agents thérapeutiques multicouche à base de particules
KR102362646B1 (ko) 2017-02-24 2022-02-11 길리애드 사이언시즈, 인코포레이티드 브루톤의 티로신 키나제의 억제제
JP2020508326A (ja) 2017-02-24 2020-03-19 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
TWI783978B (zh) 2017-03-08 2022-11-21 美商林伯士拉克許米公司 Tyk2抑制劑、其用途及生產方法
CN108570036A (zh) * 2017-03-09 2018-09-25 北京赛林泰医药技术有限公司 一种btk抑制剂的多晶型物及其制备方法
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP3375784A1 (fr) 2017-03-14 2018-09-19 Artax Biopharma Inc. Dérivés d'aza-dihydro-acridone
WO2018170067A1 (fr) * 2017-03-14 2018-09-20 Dana-Farber Cancer Institute, Inc. Sensibilisation de petites molécules à l'activation de bax pour l'induction de la mort cellulaire
EP3375778A1 (fr) 2017-03-14 2018-09-19 Artax Biopharma Inc. Dérivés d'aryl-pipéridine
WO2018175512A1 (fr) 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Inhibiteurs de tyrosine kinase de bruton
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
CN107043366B (zh) * 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
TWI776886B (zh) 2017-04-26 2022-09-11 美商奈維特製藥公司 Sestrin-gator2交互作用之調節劑及其用途
EP3615550A1 (fr) 2017-04-27 2020-03-04 BicycleTx Limited Ligands peptidiques bicycliques et leurs utilisations
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
MX2019014288A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CN109111446B (zh) 2017-06-22 2021-11-30 上海度德医药科技有限公司 一种具有药物活性的杂芳基化合物
CA3066518A1 (fr) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapie pour carcinome hepatocellulaire
US10899798B2 (en) 2017-06-26 2021-01-26 Bicyclerd Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CA3067602A1 (fr) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Modele murin pour evaluer des toxicites associees a des immunotherapies
KR102384924B1 (ko) 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019013562A1 (fr) 2017-07-12 2019-01-17 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019034868A1 (fr) 2017-08-14 2019-02-21 Bicyclerd Limited Conjugués peptide bicyclique-ligand ppr-a et leurs utilisations
EP3668887A1 (fr) 2017-08-14 2020-06-24 Bicyclerd Limited Conjugués ligands peptidiques bicycliques et leurs utilisations
CA3077739A1 (fr) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Promedicaments lipidiques orientant vers le systeme lymphatique
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
EA037031B1 (ru) * 2017-10-06 2021-01-28 Асерта Фарма Б.В. Имидазопиразиновые ингибиторы тирозинкиназы брутона
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2019126378A1 (fr) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Promédicaments lipidiques d'acide mycophénolique et leurs utilisations
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019127008A1 (fr) * 2017-12-26 2019-07-04 清华大学 Composé de dégradation ciblée de btk et son application
IL275649B2 (en) 2017-12-26 2023-12-01 Kymera Therapeutics Inc IRAK joints and used in them
CN108220261B (zh) * 2017-12-29 2021-05-14 安徽联创生物医药股份有限公司 酮还原酶、核酸、重组表达载体、重组表达菌株及应用
EP3737675A4 (fr) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Ligands crbn et leurs utilisations
WO2019140380A1 (fr) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Agents de dégradation de protéines et utilisations associées
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
EA202091742A1 (ru) 2018-02-27 2021-02-19 Артакс Биофарма Инк. ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
MX2020010437A (es) 2018-04-05 2021-01-29 Sumitomo Pharma Oncology Inc Inhibidores de axl cinasa y uso de los mismos.
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
JP7479293B2 (ja) 2018-04-24 2024-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド プテリジノン化合物およびその使用
TWI813673B (zh) 2018-04-24 2023-09-01 德商馬克專利公司 抗增生化合物及其用途
KR102106821B1 (ko) 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
EP3575300A1 (fr) 2018-05-31 2019-12-04 Apotex Inc. Nouvelles formes cristallines d'ibrutinib
IL259810A (en) 2018-06-04 2018-07-31 Yeda Res & Dev Mitogen-activated protein kinase kinase 7 inhibitors
RU2711106C2 (ru) * 2018-06-06 2020-01-15 Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе
FI3813946T3 (fi) 2018-06-15 2024-06-25 Janssen Pharmaceutica Nv Rapamysiinianalogeja ja niiden käyttötapoja
CA3100146A1 (fr) 2018-06-15 2019-12-19 Janssen Pharmaceutica Nv Formulations/compositions comprenant de l'ibrutinib
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3817748A4 (fr) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Ligands crbn tricycliques et leurs utilisations
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
CA3224985A1 (fr) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Dispersions sechees par pulverisation, formulations et polymorphies de (s)-5-amino-3-(4-((5 fluoro-2-methoxybenzamido)methyl)phenyl)(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2020045941A1 (fr) 2018-08-27 2020-03-05 주식회사 대웅제약 Nouveau dérivé d'amine hétérocyclique et composition pharmaceutique le comprenant
US20220362357A1 (en) * 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
JP2022512779A (ja) 2018-10-23 2022-02-07 バイスクルテクス・リミテッド 二環式ペプチドリガンドおよびその使用
CA3117336A1 (fr) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphies d'acide (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoique pour la modulation de mtorc1
CN111170986A (zh) 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
EP3886843A4 (fr) 2018-11-30 2022-08-31 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
KR20210117260A (ko) 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
CN113423427A (zh) 2018-11-30 2021-09-21 凯麦拉医疗公司 Irak降解剂和其用途
JP2022513689A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法におけるｂ細胞悪性腫瘍の投与および処置のための方法
EP3670659A1 (fr) 2018-12-20 2020-06-24 Abivax Biomarqueurs et leurs utilisations dans le traitement d'infections virales, d'inflammations ou du cancer
WO2020132561A1 (fr) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Dégradation ciblée de protéines
EP3669867A1 (fr) 2018-12-21 2020-06-24 Synthon B.V. Composition pharmaceutique comprenant de l'ibrutinib
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
JP2022521452A (ja) 2019-01-09 2022-04-08 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｐｉｎ１活性のモジュレータおよびその使用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CN113348021A (zh) 2019-01-23 2021-09-03 林伯士拉克许米公司 Tyk2抑制剂和其用途
WO2020167990A1 (fr) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
WO2020165600A1 (fr) 2019-02-14 2020-08-20 Bicycletx Limited Conjugués peptide-ligand bicyclique et leurs utilisations
US20240199615A1 (en) * 2019-02-19 2024-06-20 Msn Laboratories Private Limited, R&D Center Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US20220204516A1 (en) 2019-05-21 2022-06-30 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
CN113906011A (zh) 2019-05-21 2022-01-07 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
AU2020284538B2 (en) * 2019-05-28 2022-03-24 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021038540A1 (fr) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk
AU2020345962A1 (en) 2019-09-11 2022-03-31 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
EP4051259A4 (fr) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. Méthodes de traitement à l'aide d'un modulateur de mtorc1
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021113770A1 (fr) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
WO2021127283A2 (fr) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
WO2021150476A1 (fr) 2020-01-20 2021-07-29 Genzyme Corporation Inhibiteurs thérapeutiques de la tyrosine kinase pour la sclérose en plaques récurrente (rms)
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021159021A1 (fr) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Promédicaments lipidiques de neurostéroïdes
WO2021164697A1 (fr) * 2020-02-18 2021-08-26 深圳市塔吉瑞生物医药有限公司 Dérivé d'amide substitué et composition de celui-ci et son utilisation
CN115151537A (zh) 2020-02-26 2022-10-04 株式会社大熊制药 制备杂环胺衍生物的方法
CA3170411A1 (fr) 2020-03-03 2021-09-10 Christopher L. Vandeusen Inhibiteurs d'eif4e et leurs utilisations
CA3171258A1 (fr) 2020-03-19 2021-09-23 Nan JI Agents de degradation de mdm2 et leurs utilisations
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN114057724A (zh) * 2020-07-29 2022-02-18 鲁南制药集团股份有限公司 一种btk抑制剂
AU2021327130A1 (en) 2020-08-17 2023-03-02 Bicycletx Limited Bicycle conjugates specific for Nectin-4 and uses thereof
WO2022043251A1 (fr) 2020-08-28 2022-03-03 Synthon B.V. Composition pharmaceutique comprenant de l'ibrutinib
EP4203942A1 (fr) * 2020-08-28 2023-07-05 Emory University Procédés de gestion des dépendances à la cocaïne ou à d'autres drogues
WO2022120353A1 (fr) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
CN112574216B (zh) * 2020-12-16 2022-03-08 天津济坤医药科技有限公司 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用
WO2022157250A1 (fr) 2021-01-21 2022-07-28 Synthon B.V. Procédé de fabrication d'ibrutinib
WO2022167457A1 (fr) 2021-02-02 2022-08-11 Liminal Biosciences Limited Antagonistes de gpr84 et leurs utilisations
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4323066A1 (fr) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2022256417A1 (fr) * 2021-06-01 2022-12-08 Privo Technologies, Inc. Système d'administration thérapeutique localisée à base de microparticules à deux étages amélioré
US11433072B1 (en) 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2022260667A1 (fr) 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Formes posologiques orales d'ibrutinib
CN113583001A (zh) * 2021-07-13 2021-11-02 江苏君若药业有限公司 依鲁替尼的制备
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
CN115702898B (zh) * 2021-08-04 2024-02-09 成都倍特药业股份有限公司 一种btk抑制剂固体制剂及其制备方法
EP4392421A1 (fr) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
CN113845521B (zh) * 2021-08-31 2024-06-18 中原工学院 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法
WO2023071973A1 (fr) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
WO2023104808A1 (fr) 2021-12-10 2023-06-15 Synthon B.V. Composition pharmaceutique comprenant de l'ibrutinib
WO2023114984A1 (fr) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
WO2023173057A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2023173053A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
CN114605418B (zh) * 2022-03-15 2023-09-05 广东医科大学附属医院 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用
WO2023211889A1 (fr) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Composés polymorphes et leurs utilisations
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2023242384A1 (fr) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Formes cristallines d'ibrutinib
WO2023249980A1 (fr) * 2022-06-22 2023-12-28 Genzyme Corporation Procédés de fabrication d'inhibiteurs de btk modifiés
WO2024028365A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Antagonistes de gpr84 contenant de la pyridone substituée et leurs utilisations
WO2024028364A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyle et antagonistes de gpr84 apparentés et leurs utilisations
WO2024028363A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Hétéroaryl-carboxamide et antagonistes de gpr84 associés et leurs utilisations
CN115417827B (zh) * 2022-09-30 2023-05-26 中国药科大学 6-氨基-1,3,5-三嗪类化合物及其合成方法和应用
WO2024097653A1 (fr) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Inhibiteur de pim-1 pour le traitement de néoplasmes myéloprolifératifs
WO2024112894A1 (fr) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
CA2147283C (fr) 1992-10-16 2007-01-16 Kouichi Nakamichi Methode de fabrication de matrices de cire
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5530012A (en) 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CN1134439C (zh) 1997-03-19 2004-01-14 艾博特股份有限两合公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
IL139080A0 (en) * 1998-04-17 2001-11-25 Parker Hughes Inst Btx inhibitors and methods for their indentification and use
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6600744B1 (en) * 1999-03-23 2003-07-29 Alcatel Canada Inc. Method and apparatus for packet classification in a data communication system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PL354249A1 (en) 1999-09-17 2003-12-29 Abbott Gmbhabbott Gmbh Pyrazolopyrimidines as therapeutic agents
WO2001025238A2 (fr) 1999-10-06 2001-04-12 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques utiles comme inhibiteurs de tyrosine kinases
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
ITMI20010995A1 (it) * 2001-05-15 2002-11-15 Getters Spa Dispensatori di cesio e processo per il loro uso
FI20011237A0 (fi) * 2001-06-12 2001-06-12 Nokia Corp Tiedonsiirtomenetelmä ja -järjestely
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
CA2450777C (fr) 2001-08-10 2013-04-09 Novartis Ag Utilisation d'inhibiteurs c-src seuls ou en combinaison avec sti571 pour le traitement de leucemies
WO2003016338A1 (fr) 2001-08-15 2003-02-27 Parker Hughes Institute Structure cristalline du domaine kinase de btk
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
EP1939625A3 (fr) 2001-11-21 2008-09-03 Sunesis Pharmaceuticals, Inc. Procédés de découverte de ligands
US6961787B2 (en) * 2002-01-07 2005-11-01 Intel Corporation Method and apparatus for updating task files
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (fr) 2003-04-23 2004-11-25 Abbott Laboratories Procede servant a traiter le rejet d'un transplant
EP1473039A1 (fr) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20070281907A1 (en) 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
AU2005228845A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2553724A1 (fr) 2004-02-03 2005-08-18 Abbott Laboratories Utilisation d'aminobenzoxazoles comme agents therapeutiques
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
WO2006036941A2 (fr) * 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Inhibiteurs de kinases specifiques
BRPI0516166A (pt) 2004-09-28 2008-08-26 Janssen Pharmaceutica Nv antagonista do ccr2 de dipiperidina substituìda
KR20070119606A (ko) * 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
MX2007011041A (es) * 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
ATE492545T1 (de) 2005-05-13 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP1957491A2 (fr) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Derives de pyrrolo (2,3-b) pyridine utiles comme inhibiteurs de tec kinase
MX2008008642A (es) 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
JP2009525468A (ja) 2006-01-30 2009-07-09 ザ・スクリプス・リサーチ・インステイチユート 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
NZ571182A (en) * 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
SI2526933T1 (sl) 2006-09-22 2015-07-31 Pharmacyclics, Inc. Inhibitorji Bruton tirozin kinaze
EP2089391B1 (fr) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2701275C (fr) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Inhibiteurs de kinase
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
KR101955914B1 (ko) 2008-06-27 2019-03-11 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
TWI380514B (en) * 2009-07-09 2012-12-21 Hon Hai Prec Ind Co Ltd Electronic connector and electronic device using the same
SG179172A1 (en) 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
NZ789041A (en) 2010-06-03 2023-09-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
MY162132A (en) 2010-06-23 2017-05-31 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CA2807051A1 (fr) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Sel de besylate d'un inhibiteur de btk
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
SG11201408067YA (en) 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
MX2015016277A (es) 2013-05-30 2016-08-11 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
EP3027192A4 (fr) 2013-08-02 2017-03-22 Pharmacyclics, LLC Méthodes permettant de traiter des tumeurs solides
WO2015061752A1 (fr) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
CN106008521A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
US7825118B2 (en) 2010-11-02
EP2526934B1 (fr) 2015-12-09
HUE033182T2 (en) 2017-11-28
US20120214826A1 (en) 2012-08-23
KR20090091115A (ko) 2009-08-26
CN102746305B (zh) 2015-02-11
PL2201840T3 (pl) 2012-03-30
CY2016041I1 (el) 2017-03-15
US8158786B2 (en) 2012-04-17
HK1140107A1 (en) 2010-10-08
US20120122894A1 (en) 2012-05-17
US20110184001A1 (en) 2011-07-28
EA024255B1 (ru) 2016-08-31
LT2530083T (lt) 2016-09-26
US20180085372A1 (en) 2018-03-29
FR15C0029I1 (fr) 2015-05-15
EP2443929A1 (fr) 2012-04-25
EP2201840A1 (fr) 2010-06-30
PT2530083T (pt) 2016-08-01
US9127012B2 (en) 2015-09-08
US7960396B2 (en) 2011-06-14
US8957079B2 (en) 2015-02-17
ES2585902T3 (es) 2016-10-10
US20140171453A1 (en) 2014-06-19
KR101479913B1 (ko) 2015-01-08
EP2201840B1 (fr) 2011-11-02
EP2526771A1 (fr) 2012-11-28
CY2015016I1 (el) 2016-04-13
LTC2201840I2 (lt) 2016-12-27
US20120088912A1 (en) 2012-04-12
KR101464424B1 (ko) 2014-11-27
US20140275125A1 (en) 2014-09-18
US8232280B2 (en) 2012-07-31
JP5193256B2 (ja) 2013-05-08
US20120095026A1 (en) 2012-04-19
SI2526933T1 (sl) 2015-07-31
WO2008039218A3 (fr) 2008-05-29
SI2526934T1 (sl) 2016-04-29
CN101805341B (zh) 2013-07-24
AU2006348662A1 (en) 2008-04-03
PL2081435T3 (pl) 2016-11-30
US8735403B2 (en) 2014-05-27
US9133202B2 (en) 2015-09-15
SG166093A1 (en) 2010-11-29
EP2530083A1 (fr) 2012-12-05
US20080139582A1 (en) 2008-06-12
KR101315610B1 (ko) 2013-10-10
CA2663116C (fr) 2014-06-10
US8703780B2 (en) 2014-04-22
US20100041677A1 (en) 2010-02-18
EP2081435A4 (fr) 2010-03-17
US8658653B2 (en) 2014-02-25
AU2006348662B2 (en) 2012-04-19
CY1116295T1 (el) 2017-02-08
JP2012105681A (ja) 2012-06-07
HK1129274A1 (zh) 2009-11-27
US8759516B2 (en) 2014-06-24
JP4934197B2 (ja) 2012-05-16
PL2526934T3 (pl) 2016-06-30
US8975266B2 (en) 2015-03-10
PL2526933T3 (pl) 2015-08-31
US20120129821A1 (en) 2012-05-24
KR20140022112A (ko) 2014-02-21
US20140163046A1 (en) 2014-06-12
US20140039186A1 (en) 2014-02-06
MX347525B (es) 2017-04-27
US7514444B2 (en) 2009-04-07
US20100331350A1 (en) 2010-12-30
NZ595230A (en) 2013-02-22
LT2529622T (lt) 2018-05-10
CY1117840T1 (el) 2017-05-17
CN102887900B (zh) 2015-04-29
PL2526934T4 (pl) 2016-09-30
US20100254905A1 (en) 2010-10-07
PL2529621T3 (pl) 2017-06-30
NL300728I1 (fr) 2016-01-26
NL300728I2 (fr) 2016-01-26
US20090181987A1 (en) 2009-07-16
US8552010B2 (en) 2013-10-08
ES2376424T3 (es) 2012-03-13
SI2201840T1 (sl) 2012-06-29
US20170007611A1 (en) 2017-01-12
US20120115889A1 (en) 2012-05-10
US20120277254A1 (en) 2012-11-01
LTPA2016034I1 (lt) 2016-12-27
NZ575650A (en) 2011-10-28
HUS1600049I1 (hu) 2017-01-30
BRPI0622054A2 (pt) 2010-11-09
EP2526933B1 (fr) 2015-02-25
US20120252821A1 (en) 2012-10-04
CY2015016I2 (el) 2018-01-10
ZA201100893B (en) 2013-03-27
US20140187564A1 (en) 2014-07-03
EP2526771B1 (fr) 2016-11-30
JP2010235628A (ja) 2010-10-21
CY1120135T1 (el) 2018-12-12
US8697711B2 (en) 2014-04-15
HUS1700012I1 (hu) 2017-05-29
JP5718890B2 (ja) 2015-05-13
EA200900351A1 (ru) 2009-10-30
SG10201503235VA (en) 2015-06-29
BRPI0622277A2 (pt) 2011-08-09
HUE028712T2 (en) 2016-12-28
LT2529621T (lt) 2017-01-10
LUC00011I1 (fr) 2017-04-06
US8883435B2 (en) 2014-11-11
US9133201B2 (en) 2015-09-15
EP2526933A2 (fr) 2012-11-28
US8691546B2 (en) 2014-04-08
ES2616789T3 (es) 2017-06-14
ES2673973T3 (es) 2018-06-26
CA3180977A1 (fr) 2008-04-03
ES2584331T3 (es) 2016-09-27
BRPI0622054B1 (pt) 2018-02-06
US20140212485A1 (en) 2014-07-31
CA2663116A1 (fr) 2008-04-03
US8735404B2 (en) 2014-05-27
US20120283277A1 (en) 2012-11-08
AU2006348662B8 (en) 2014-05-29
CY2017012I1 (el) 2017-11-14
US20110281322A1 (en) 2011-11-17
US20200108072A1 (en) 2020-04-09
EP2532235A1 (fr) 2012-12-12
CN101610676B (zh) 2013-03-27
DK2526933T3 (en) 2015-05-18
US20140135347A1 (en) 2014-05-15
CN102887900A (zh) 2013-01-23
US20220008424A1 (en) 2022-01-13
PT2201840E (pt) 2012-02-14
CY1119209T1 (el) 2017-11-14
US8399470B2 (en) 2013-03-19
US8501751B2 (en) 2013-08-06
US20120129873A1 (en) 2012-05-24
US20110008257A1 (en) 2011-01-13
US20140128413A1 (en) 2014-05-08
US9193735B2 (en) 2015-11-24
LTPA2017009I1 (lt) 2017-04-25
PT2526933E (pt) 2015-06-23
DK2201840T3 (da) 2012-02-20
KR20100051863A (ko) 2010-05-18
US20140187565A1 (en) 2014-07-03
SI2526771T1 (sl) 2017-06-30
HUE031334T2 (hu) 2017-07-28
CN101610676A (zh) 2009-12-23
CY2017012I2 (el) 2017-11-14
KR20130027536A (ko) 2013-03-15
US20110257203A1 (en) 2011-10-20
DK2081435T3 (en) 2016-08-15
SI2530083T1 (sl) 2016-09-30
US20100324050A1 (en) 2010-12-23
US8497277B2 (en) 2013-07-30
EA018573B1 (ru) 2013-09-30
ES2617150T3 (es) 2017-06-15
DK2529621T3 (en) 2017-01-16
US9266893B2 (en) 2016-02-23
WO2008039218A2 (fr) 2008-04-03
US8754091B2 (en) 2014-06-17
PT2529622T (pt) 2018-04-24
PT2529621T (pt) 2016-12-23
CY1117897T1 (el) 2017-05-17
EP2529622A1 (fr) 2012-12-05
US8563563B2 (en) 2013-10-22
MX2019012657A (es) 2019-12-11
DK2526934T3 (en) 2016-03-07
US20120108612A1 (en) 2012-05-03
US8741908B2 (en) 2014-06-03
HK1178144A1 (en) 2013-09-06
HUE028086T2 (en) 2016-11-28
SI2081435T1 (sl) 2016-10-28
CN101805341A (zh) 2010-08-18
US20120135944A1 (en) 2012-05-31
US20140142123A1 (en) 2014-05-22
US9409911B2 (en) 2016-08-09
ZA201207075B (en) 2013-06-26
ES2537399T3 (es) 2015-06-08
EP2526934A2 (fr) 2012-11-28
US8236812B2 (en) 2012-08-07
US20140336206A1 (en) 2014-11-13
EP2526934A3 (fr) 2012-12-05
IL197550A0 (en) 2009-12-24
US7732454B2 (en) 2010-06-08
EA020001B1 (ru) 2014-07-30
US20150306103A1 (en) 2015-10-29
US20110039868A1 (en) 2011-02-17
CY1112513T1 (el) 2015-12-09
ES2564647T3 (es) 2016-03-28
US20140243355A1 (en) 2014-08-28
HUE036897T2 (hu) 2018-08-28
ZA200901784B (en) 2011-01-26
FR15C0029I2 (fr) 2015-11-13
US8008309B2 (en) 2011-08-30
DK2529622T3 (en) 2018-05-07
CY1117587T1 (el) 2017-03-15
AU2010201052B2 (en) 2012-03-15
HUE029095T2 (en) 2017-02-28
EP2529621A1 (fr) 2012-12-05
US8088781B2 (en) 2012-01-03
EP2526933A3 (fr) 2012-12-05
ES2616789T8 (es) 2020-12-09
CY1118666T1 (el) 2017-07-12
AU2010201052A1 (en) 2010-04-08
EP2532234A1 (fr) 2012-12-12
US8748438B2 (en) 2014-06-10
EP2081435B1 (fr) 2016-05-04
EP2529622B1 (fr) 2018-01-17
US20120283276A1 (en) 2012-11-08
BRPI0622054B8 (pt) 2021-05-25
US8748439B2 (en) 2014-06-10
US8952015B2 (en) 2015-02-10
SI2529621T1 (sl) 2017-04-26
NZ601278A (en) 2013-09-27
LT2526771T (lt) 2017-06-12
US20100022561A1 (en) 2010-01-28
MX2009003122A (es) 2009-08-07
CN102746305A (zh) 2012-10-24
ATE531263T1 (de) 2011-11-15
US8476284B2 (en) 2013-07-02
EP2081435A2 (fr) 2009-07-29
LUC00011I2 (fr) 2017-05-30
US9181257B2 (en) 2015-11-10
EA201000599A1 (ru) 2011-02-28
PL2529622T3 (pl) 2018-07-31
SI2529622T1 (en) 2018-06-29
US20120252822A1 (en) 2012-10-04
EA201300246A1 (ru) 2014-01-30
DK2526771T3 (en) 2017-02-27
ZA201007561B (en) 2012-09-26
EP2530083B1 (fr) 2016-04-27
HUE025459T2 (hu) 2016-05-30
PL2526771T3 (pl) 2017-06-30
PL2530083T3 (pl) 2016-11-30
PT2081435T (pt) 2016-08-04
CY2016041I2 (el) 2017-03-15
PT2526771T (pt) 2017-02-27
US20080076921A1 (en) 2008-03-27
HUS1500018I1 (hu) 2017-10-30
JP5635544B2 (ja) 2014-12-03
US20140128414A1 (en) 2014-05-08
EP2529621B1 (fr) 2016-10-05
US20080108636A1 (en) 2008-05-08
US20130005745A1 (en) 2013-01-03
US9133198B2 (en) 2015-09-15
JP2013060466A (ja) 2013-04-04
US9212185B2 (en) 2015-12-15
JP2010504324A (ja) 2010-02-12
US20100004270A1 (en) 2010-01-07
US9206189B2 (en) 2015-12-08
LU92692I2 (fr) 2015-11-24
CA2847852A1 (fr) 2008-04-03

Similar Documents

Publication Publication Date Title
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci